To include your compound in the COVID-19 Resource Center, submit it here.

J&J opts in for Idorsia's hypertension candidate

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577)

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE